Kaleb C. Bierstedt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kaleb C. Bierstedt has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Yuliang Xie
University of Iowa
2 shared publications - Alejandro A. Pezzulo
University of Iowa
1 shared publication - Ashley L. Cooney
University of Iowa
1 shared publication - Brandon S. J. Davies
University of Iowa
1 shared publication Brian J. Goodell
Pappajohn Biomedical Institute, The University of Iowa, Iowa City, IA, USA
1 shared publicationHuiyu Gong
Pappajohn Biomedical Institute, The University of Iowa, Iowa City, IA, USA
1 shared publication
Latest Publications
- Open Access
- 21 November 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (47) , eady4866
Porcine airway tissue explant culture at a hydrogel-air interface to model submucosal glands in cystic fibrosis progression and therapy
Submucosal glands (SMGs) are critical for airway health; however, replicating their complex structure and function outside the body remains challenging. Here, we establish a method of airway tissue explant culture at a hydrogel-air interface (i.e., AirTECH) using trachea from newborn pigs. After 14 days, AirTECH tissues maintain their natural SMG structures, cell types, gene expression, and defense functions, along with intact surface epithelia, smooth muscle, and cartilage. Using AirTECH tissue as a model, we evaluated SMGs in cystic fibrosis (CF) airway disease progression, where exposure to lipopolysaccharide of Pseudomonas aeruginosa caused abnormal mucus obstruction and overexpression of MUC5AC in SMGs, a characteristic feature of CF airway disease. We also explored the contribution of SMGs in airway gene therapy, where green fluorescent protein–encoding adenovirus vectors were transduced and expressed exclusively in airway surface epithelia but not SMGs. These data support AirTECH as a model to understand SMGs in airway disease and test therapeutic interventions.
- 21 November 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (47) , eady4866
Open AccessPorcine airway tissue explant culture at a hydrogel-air interface to model submucosal glands in cystic fibrosis progression and therapy
Submucosal glands (SMGs) are critical for airway health; however, replicating their complex structure and function outside the body remains challenging. Here, we establish a method of airway tissue explant culture at a hydrogel-air interface (i.e., AirTECH) using trachea from newborn pigs. After 14 days, AirTECH tissues maintain their natural SMG structures, cell types, gene expression, and defense functions, along with intact surface epithelia, smooth muscle, and cartilage. Using AirTECH tissue as a model, we evaluated SMGs in cystic fibrosis (CF) airway disease progression, where exposure to lipopolysaccharide of Pseudomonas aeruginosa caused abnormal mucus obstruction and overexpression of MUC5AC in SMGs, a characteristic feature of CF airway disease. We also explored the contribution of SMGs in airway gene therapy, where green fluorescent protein–encoding adenovirus vectors were transduced and expressed exclusively in airway surface epithelia but not SMGs. These data support AirTECH as a model to understand SMGs in airway disease and test therapeutic interventions.
- Open Access
- 23 May 2024
- Published by Royal Society of Chemistry (RSC) in Lab on a Chip
- Vol. 24 (12) , 3093-3100
Dynamic measurement of airway surface liquid volume with an ex vivo trachea-chip
An “ ex vivo trachea chip” integrates a tissue explant with a micromachined device, enables dynamic measurements of airway surface liquid volume, and reveals physiology of airway surface liquid secretion and absorption.
- 23 May 2024
- Published by Royal Society of Chemistry (RSC) in Lab on a Chip
- Vol. 24 (12) , 3093-3100
Open AccessDynamic measurement of airway surface liquid volume with an ex vivo trachea-chip
An “ ex vivo trachea chip” integrates a tissue explant with a micromachined device, enables dynamic measurements of airway surface liquid volume, and reveals physiology of airway surface liquid secretion and absorption.
- Open Access
Endothelial Lipase Variant, T111I, Does Not Alter Inhibition by Angiopoietin-like Proteins
High levels of HDL-C are correlated with a decreased risk of cardiovascular disease. HDL-C levels are modulated in part by the secreted phospholipase, endothelial lipase (EL), which hydrolyzes the phospholipids of HDL and decreases circulating HDL-C concentrations. A 584C/T polymorphism in LIPG , the gene which encodes EL, was first identified in individuals with increased HDL levels. This polymorphism results in a T111I point mutation the EL protein. The association between this variant, HDL levels, and the risk of coronary artery disease (CAD) in humans has been extensively studied, but the findings have been inconsistent. In this study, we took a biochemical approach, investigating how the T111I variant affected EL activity, structure, and stability. Moreover, we tested whether the T111I variant altered the inhibition of phospholipase activity by angiopoietin-like 3 (ANGPTL3) and angiopoietin-like 4 (ANGPTL4), two known EL inhibitors. We found that neither the stability nor enzymatic activity of EL was altered by the T111I variant. Moreover, we found no difference between wild-type and T111I EL in their ability to be inhibited by ANGPTL proteins. These data suggest that any effect this variant may have on HDL-C levels or cardiovascular disease are not mediated through alterations in these functions.
Open AccessEndothelial Lipase Variant, T111I, Does Not Alter Inhibition by Angiopoietin-like Proteins
High levels of HDL-C are correlated with a decreased risk of cardiovascular disease. HDL-C levels are modulated in part by the secreted phospholipase, endothelial lipase (EL), which hydrolyzes the phospholipids of HDL and decreases circulating HDL-C concentrations. A 584C/T polymorphism in LIPG , the gene which encodes EL, was first identified in individuals with increased HDL levels. This polymorphism results in a T111I point mutation the EL protein. The association between this variant, HDL levels, and the risk of coronary artery disease (CAD) in humans has been extensively studied, but the findings have been inconsistent. In this study, we took a biochemical approach, investigating how the T111I variant affected EL activity, structure, and stability. Moreover, we tested whether the T111I variant altered the inhibition of phospholipase activity by angiopoietin-like 3 (ANGPTL3) and angiopoietin-like 4 (ANGPTL4), two known EL inhibitors. We found that neither the stability nor enzymatic activity of EL was altered by the T111I variant. Moreover, we found no difference between wild-type and T111I EL in their ability to be inhibited by ANGPTL proteins. These data suggest that any effect this variant may have on HDL-C levels or cardiovascular disease are not mediated through alterations in these functions.